A Randomized, Placebo-controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Intranasal STI-2099 (COVI-DROPS) in Outpatient Adults With COVID-19
Latest Information Update: 07 Feb 2022
At a glance
- Drugs STI-2099 (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Sponsors Sorrento Therapeutics
- 21 Jan 2022 Status changed from active, no longer recruiting to completed.
- 19 Jan 2022 According to a Sorrento Therapeutics media release, the company expects results from this trial in the coming months.
- 19 Jan 2022 Results published in Sorrento Therapeutics Media Release.